Adjunct Therapy with Ipragliflozin Exerts Limited Effects on Kidney Protection in Type 1 Diabetes: A Retrospective Study Conducted at 25 Centers in Japan (IPRA-CKD)

<b>Background/Objectives</b>: While sodium–glucose cotransporter 2 (SGLT2) inhibitors have demonstrated additional non-glycemic benefits for renal protection in individuals with type 2 diabetes, less evidence is available for those with type 1 diabetes (T1D). To determine whether the adjunctive use...

Descripció completa

Dades bibliogràfiques

Autors principals:	Yuta Nakamura, Ichiro Horie, Hiroshi Yano, Hiroshi Nomoto, Tomoyasu Fukui, Yoshihiko Yuyama, Tomoyuki Kawamura, Mariko Ueda, Akane Yamamoto, Yushi Hirota, Yoshiki Kusunoki, Kenro Nishida, Dan Sekiguchi, Yasutaka Maeda, Masae Minami, Ayako Nagayama, Shimpei Iwata, Hitomi Minagawa, Shinya Furukawa, Teruki Miyake, Hiroaki Ueno, Rei Chinen, Yoshiro Nakayama, Hiroaki Masuzaki, Yasutaka Miyachi, Yosuke Okada, Mitsuhiro Okamoto, Kaoru Ono, Ken-ichi Tanaka, Akira Kurozumi, Takenori Sakai, Hironori Yamasaki, Jun-ichi Yasui, Ayako Ito, Atsushi Kawakami, Norio Abiru
Format:	Artigo
Idioma:	Inglês
Publicat:	MDPI AG 2025-05-01
Col·lecció:	Biomedicines
Matèries:	ipragliflozin type 1 diabetes SGLT2 inhibitor chronic kidney disease renal outcome
Accés en línia:	https://www.mdpi.com/2227-9059/13/6/1287
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!